Vividion, Robert Abraham
After 10 years of working for Pfizer, Robert Abraham leaves the role of SVP and group head of Oncology R&D at the pharma giant to take over as the CSO of Vividion Therapeutics.
Abraham joined Pfizer in 2009 following the acquisition of Wyeth, where he was VP and head of Oncology Discovery.
Vividion was launched in 2017 as a spin-out from The Scripps Research Institute in La Jolla, US, to develop small molecule drug products for traditionally inaccessible targets, working on the fields of oncology and immunology.
In April 2019, the company raised $82m (€74.1m) in Series B financing to support its research based on a platform that enables screening of small molecules against proteins in native biological systems.
